Original from: Waters ¡¤ Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters¡¯ proven execution model ¡¤ Doubles Wate..

Personalis said this week that it has extended its strategic collaboration with Tempus AI to include colorectal cancer (CRC) among the indications covered by their existing, exclusive commercialization agreement.

Claret Bioscience, a pioneer in next-generation sequencing (NGS) library preparation technologies for challenging samples, and Hamilton Company, a global leader in precision laboratory automation, are proud to announce a strategic co-promotion initiative. This collaboration aims to accelerate and simplify workflows for throughput NGS library preparation by delivering validated automation protocols for ClaretBio¡¯s SRSLY® and REALLY™ product lines on Hamilton¡¯s NGS STAR liquid handling platforms.

The National Medical Products Administration (NMPA) of China has introduced a series of strategic measures to accelerate the development of new-quality productivity in the high-end medical device sector.

Original from: Access Newswire VieCure Inc., pioneer of an intelligent cancer care ecosystem that democratizes precision oncology for community-based practices, today announced a strategic partnership wit..

The UK government said Thursday that it will align its regulations on high-risk in vitro diagnostic devices that are sold in Great Britain to align with EU specifications and repeal regulations specific to COVID-19 tests.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today a new initiative with NOWDiagnostics (NOWDx), a leader in developing over-the-counter (OTC) and point-of-care (POC) diagnostic tests, to expand access to rapid syphilis testing. The companies will distribute First to Know® Syphilis Test kits at no cost to select community-based public health organizations across the country.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/¦Â-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.

Leinco Technologies, a leading global provider of in vitro diagnostic (IVD) raw materials, today announced the acquisition of BioClin, Inc.¡¯s proprietary antibody clones used as IVD raw materials. This strategic partnership significantly expands Leinco¡¯s portfolio of critical reagents for endocrine hormone research and diagnostic assays.

Quanterix Corporation (¡°Quanterix¡± or the ¡°Company¡±) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets.

The POCT Market 1. International Market Conditions The POCT market is large and has enjoyed sound growth. From 2008 to 2018, the sales volume of the global POCT market doubled, with an average annu..

Siemens Healthineers Officially Launches First APAC Production Line for Laboratory Diagnostics Equipment Siemens Healthineers' first domestically produced high-end laboratory diagnostics system¡ªthe Atel..

Noul said it has signed a memorandum of understanding (MOU) with Seegene Brazil to introduce its AI-based cervical cancer diagnostic solution, miLab CER, to the Brazilian market.

MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate MedMira¡¯s Multiplo® TP/HIV rapid test for use as a self-test in Canada.

China enacted new measures, effective immediately, targeting the procurement of certain medical devices imported from the European Union in government purchasing programs, according to a notice issued by the Ministry of Finance on Sunday.

Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal¡¯s ZEGFROVY® (sunvozertinib) and in tumor profiling. This approval brings rapid next-generation sequencing (NGS) to decentralized clinical settings closer to where patients receive care. With the ability to deliver essential genomic insights in as little as 24 hours*, this approval helps advance the accessibility of precision oncology tools and enables more timely decision making.

8. Molecular POCT Technology Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy. However, traditional nucleic acid detection pro..

The TOBY Test has received breakthrough device designation from the FDA for the early detection of bladder cancer. This designation underscores the significant potential of this innovative urine-based assay to fundamentally alter the landscape of bladder cancer detection and surveillance, offering a much-needed non-invasive alternative to current diagnostic paradigms.

Merck, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions.

Danaher Invests CNY 200 million to Expand R&D and Manufacturing Base in Shanghai Leica Microsystems, a subsidiary of Danaher, signed an agreement to invest CNY 200 million in expanding..